|
|
Article: Adolor, With Partner GSK, Initiate Entereg Phase III.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Washington Editor
Partners Adolor Corp. and GlaxoSmithKline plc began a broad Phase III program to investigate the use of Entereg (alvimopan) for opioid-induced constipation and associated symptoms.
"The results from Phase IIb studies were very positive and very encouraging," said James Barrett, a senior vice president at Adolor and its chief scientific officer. "I think the shear, overwhelming positive nature of those studies provided a lot of impetus to really get [Phase III] going very quickly."
The international program is made of three studies expected to enroll about 1,700 patients in North America, Europe and other parts of the world. ...
Related newspaper, magazine, and journal articles:
|